Pulmatrix Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PULM Nasdaq 8731 https://www.pulmatrix.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pulmatrix Inc

Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023) - Aug 15th, 2024 10:30 am
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Aug 13th, 2024 1:05 pm
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - May 29th, 2024 12:45 pm
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - May 15th, 2024 1:00 pm
Pulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023) - May 12th, 2024 1:50 pm
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update - May 10th, 2024 12:05 pm
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update - Mar 28th, 2024 1:05 pm
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives - Jan 8th, 2024 2:00 pm
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Nov 9th, 2023 2:05 pm